Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 7:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 34 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: fluvoxamine Clear all
Recruiting No phase listed Observational

Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants

NCT03511118
View directory record Official record
Conditions
Lactating Women on Select DOI, Breastfed Infants of Mothers on Select DOI
Interventions
Tranexamic acid (TXA), labetalol, metformin, nifedipine, clindamycin, oxycodone, azithromycin, escitalopram, sertraline, ondansetron, Ciprofloxacin, Doxycycline, Levofloxacin, Methylphenidate, Sumatriptan, Citalopram, Cyclobenzaprine, Furosemide, Gabapentin, Hydrochlorothiazide, Hydroxyurea, Rosuvastatin, Topiramate, Trazodone, Valganciclovir, Venlafaxine, Verapamil, Remdesivir, Anakinra, Tocilizumab, Fluvoxamine, Amoxicillin, Bupropion, Duloxetine, Hydrocodone, Levetiracetam, Paroxetine, Buprenorphine
Drug
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
20
States / cities
La Jolla, California • Loma Linda, California • Chicago, Illinois + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 20, 2026, 7:37 AM EDT
Completed No phase listed Observational

YouScript IMPACT Registry

NCT02191358
View directory record Official record
Conditions
Adverse Drug Events, Adverse Drug Reactions, Drug Interaction Potentiation, Drug Metabolism, Poor, CYP2D6-RELATED, Drug Metabolism, Poor, CYP2C19-RELATED, Cytochrome P450 Enzyme Deficiency, Cytochrome P450 CYP2D6 Enzyme Deficiency, Cytochrome P450 CYP2C9 Enzyme Deficiency, Cytochrome P450 CYP2C19 Enzyme Deficiency, Cytochrome P450 CYP3A Enzyme Deficiency, Poor Metabolizer Due to Cytochrome P450 CYP2C9 Variant, Poor Metabolizer Due to Cytochrome P450 CYP2C19 Variant, Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant
Interventions
Not listed
Lead sponsor
Genelex Corporation
Industry
Eligibility
65 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
7
States / cities
Garden Grove, California • Denver, Colorado • Lexington, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2017 · Synced Oct 20, 2026, 7:37 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Fluvoxamine for Long COVID-19

NCT05874037
View directory record Official record
Conditions
Long COVID
Interventions
Fluvoxamine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
25 Years and older
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 20, 2026, 7:37 AM EDT
Completed Phase 3 Interventional Results available

ACTIV-6: COVID-19 Study of Repurposed Medications - Arm E (Fluvoxamine 100)

NCT05894564
View directory record Official record
Conditions
Covid19
Interventions
Fluvoxamine, Placebo
Drug · Other
Lead sponsor
Susanna Naggie, MD
Other
Eligibility
30 Years and older
Enrollment
1,208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
103
States / cities
Gilbert, Arizona • Mesa, Arizona • Peoria, Arizona + 90 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2024 · Synced Oct 20, 2026, 7:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Characterize the Effects of Cytochrome p450 1A2 Inhibition on Systemic Exposure to BMS-986165

NCT03930602
View directory record Official record
Conditions
Healthy
Interventions
BMS-986165, Fluvoxamine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 17, 2021 · Synced Oct 20, 2026, 7:37 AM EDT
Withdrawn Phase 2 Interventional

Fluvoxamine to Augment Olfactory Recovery For Long COVID-19 Parosmia

NCT05216614
View directory record Official record
Conditions
COVID-19, Olfactory Disorder, Parosmia
Interventions
Fluvoxamine, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 11, 2022 · Synced Oct 20, 2026, 7:37 AM EDT
Completed Phase 3 Interventional Results available

COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19)

NCT04510194
View directory record Official record
Conditions
Covid19, SARS-CoV Infection
Interventions
Metformin, Placebo, Fluvoxamine, Ivermectin
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
30 Years to 85 Years
Enrollment
1,323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
Sylmar, California • Aurora, Colorado • Golden, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 20, 2026, 7:37 AM EDT
Completed Phase 1 Interventional

Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors.

NCT01700270
View directory record Official record
Conditions
Advanced Solid Tumors, Excluding Breast Cancer
Interventions
dovitinib (TKI258), fluvoxamine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
The Bronx, New York • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Oct 20, 2026, 7:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effects of Fluvoxamine on Savolitinib Exposure in Healthy Male Subjects

NCT05888207
View directory record Official record
Conditions
Healthy Male Subjects
Interventions
Savolitinib, Fluvoxamine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced Oct 20, 2026, 7:37 AM EDT
Completed Not applicable Interventional Results available

Implementing Genomics in Practice (IGNITE): CYP2D6 Genotype-Guided Pain Management in Patients Undergoing Arthroplasty Surgery

NCT03534063
View directory record Official record
Conditions
Pain, Postoperative
Interventions
CYP2D6-guided opioid therapy
Genetic
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
3
States / cities
Gainesville, Florida • Summerfield, Florida
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced Oct 20, 2026, 7:37 AM EDT
Completed Phase 4 Interventional

Predicting Treatment Response in Patients With OCD

NCT03993535
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
selective serotonin reuptake inhibitor
Drug
Lead sponsor
University of Sao Paulo
Other
Eligibility
18 Years to 50 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 20, 2026, 7:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating the Effects of Food, Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of CC-122

NCT03340662
View directory record Official record
Conditions
Healthy Volunteer
Interventions
CC-122, Itraconazole, Fluvoxamine, Rifampin
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 16, 2019 · Synced Oct 20, 2026, 7:37 AM EDT
Completed Phase 4 Interventional Results available

Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With TRD

NCT02977299
View directory record Official record
Conditions
Treatment Resistant Major Depressive Disorder
Interventions
Aripiprazole, Repetitive transcranial magnetic stimulation (rTMS), Venlafaxine XR
Drug · Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • Stanford, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 20, 2026, 7:37 AM EDT
Completed Not applicable Interventional

Treatment of Youth With ADHD and Anxiety

NCT00012584
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Anxiety, Separation, Social Phobia, Generalized Anxiety Disorder
Interventions
methylphenidate, fluvoxamine
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
6 Years to 17 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
5
States / cities
Los Angeles, California • Baltimore, Maryland • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2009 · Synced Oct 20, 2026, 7:37 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Supplemental Transcranial Magnetic Stimulation (TMS) vs. Standard Medication Monotherapy for Treating Major Depression: An Exploratory Field Study

NCT01944657
View directory record Official record
Conditions
1. Major Depressive Disorder
Interventions
Supplemental TMS, Standard Medication Monotherapy
Device · Drug
Lead sponsor
Sheppard Pratt Health System
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Towson, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Oct 20, 2026, 7:37 AM EDT
Completed Phase 2 Interventional Results available

An Adaptive Algorithm-Based Approach to Treatment for Adolescent Depression

NCT03222570
View directory record Official record
Conditions
Depressive Disorder
Interventions
Interpersonal Psychotherapy for Depressed Adolescents, Selective Serotonin Reuptake Inhibitor, Usual Care
Behavioral · Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
12 Years to 18 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Oct 20, 2026, 7:37 AM EDT
Completed Phase 3 Interventional Results available

Fluvoxamine for Early Treatment of Covid-19 (Stop Covid 2)

NCT04668950
View directory record Official record
Conditions
Covid19, Coronavirus
Interventions
Fluvoxamine, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
30 Years and older
Enrollment
670 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
4
States / cities
Chicago, Illinois • St Louis, Missouri • Salt Lake City, Utah + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2022 · Synced Oct 20, 2026, 7:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

AV650 Drug-Drug Interaction Study

NCT00456560
View directory record Official record
Conditions
Healthy
Interventions
AV650, Fluvoxamine, Paroxetine
Drug
Lead sponsor
Avigen
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2007 · Synced Oct 20, 2026, 7:37 AM EDT
Completed Phase 2 Interventional Results available

A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection

NCT04342663
View directory record Official record
Conditions
COVID 19, Coronavirus
Interventions
Fluvoxamine, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
2
States / cities
Belleville, Illinois • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 9, 2021 · Synced Oct 20, 2026, 7:37 AM EDT
Completed Phase 3 Interventional Results available

Treatment of Obsessive Compulsive Disorder in Children

NCT00074815
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Serotonin reuptake inhibitors management, Cognitive behavioral therapy by a psychologist, Instructional cognitive behavioral therapy by a psychiatrist
Drug · Behavioral
Lead sponsor
Duke University
Other
Eligibility
7 Years to 17 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
3
States / cities
Durham, North Carolina • Philadelphia, Pennsylvania • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 29, 2014 · Synced Oct 20, 2026, 7:37 AM EDT
Completed Phase 2 Interventional Results available

A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy

NCT03321526
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
JNJ-42847922, Placebo Matching to JNJ-42847922, Quetiapine XR, Placebo Matching to Quetiapine XR, Selective Serotonin Reuptake Inhibitor (SSRI), Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
50
States / cities
Phoenix, Arizona • Tempe, Arizona • Rogers, Arkansas + 41 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 20, 2026, 7:37 AM EDT
Completed Phase 3 Interventional Results available

ACTIV-6: COVID-19 Study of Repurposed Medications

NCT04885530
View directory record Official record
Conditions
Covid19
Interventions
Ivermectin, Fluvoxamine, Fluticasone, Placebo, Montelukast, Metformin
Drug · Other
Lead sponsor
Susanna Naggie, MD
Other
Eligibility
30 Years and older
Enrollment
10,956 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
110
States / cities
Chandler, Arizona • Gilbert, Arizona • Mesa, Arizona + 96 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Oct 20, 2026, 7:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction (DDI) Study for TD-9855

NCT03432793
View directory record Official record
Conditions
Drug Drug Interaction (DDI)
Interventions
TD-9855, Fluvoxamine, Itraconazole, Caffeine
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
19 Years to 55 Years · Male only
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 14, 2021 · Synced Oct 20, 2026, 7:37 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Cost-Effectiveness of Adding Web-Based Cognitive-Behavioral Therapy (CBT) to Luvox CR for Obsessive Compulsive Disorder (OCD)

NCT00743834
View directory record Official record
Conditions
Obsessive Compulsive Disorder
Interventions
Luvox CR, Behavioral Therapy
Drug · Behavioral
Lead sponsor
Rogers Center for Research & Training, Inc.
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 4, 2008 · Synced Oct 20, 2026, 7:37 AM EDT